Why Lasmiditan?

Lasmiditan is a member of a novel drug class called "ditans".

Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5‑HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan

Lasmiditan does not interact with vasoconstrictor 5‑HT1B/1D receptors activated by triptans.

No evidence of drug-related cardiovascular adverse effects or chest symptoms in the previous seven clinical studies.

Learn More About Lasmiditan

Seven clinical studies provide Proof of Concept in the acute treatment of migraine attacks.

Learn More About Lasmiditan

Development Plan

Phase 2b Proof of Concept

Lasmiditan SP-Agreement

IV Lasmiditan Phase 2 Proof of Concept

Meet CoLucid

Daniel L. Boeglin

Secretary and Legal Counsel

Dan Boeglin is a partner with Faegre Baker Daniels LLP. He has represented leading pharmaceutical, medical device and biotechnology companies in…

Read More Meet The Others

About Migraines


A migraine is a painful neurological condition, of which the most common symptom is an intense and disabling headache.

Learn More About Migraines